Sign in

    John Janco

    Managing Director and Senior Equity Research Analyst at Needham & Company

    John Janco is a Managing Director and Senior Equity Research Analyst at Needham & Company, specializing in coverage of the communications and technology sectors. He is recognized for his in-depth research on companies such as Ribbon Communications, DZS Inc., CommScope, and Calix, delivering insightful analysis and actionable investment recommendations. With over two decades in equity research, Janco joined Needham & Company in the early 2000s after experience at firms including Ladenburg Thalmann, and has consistently ranked among top analysts on platforms like TipRanks with a track record of outperforming sector benchmarks. He holds multiple FINRA securities licenses and maintains Series 7, 63, 86, and 87 certifications, reflecting his deep expertise and regulatory compliance.

    John Janco's questions to CorMedix (CRMD) leadership

    John Janco's questions to CorMedix (CRMD) leadership • Q2 2024

    Question

    John Janco, on for Serge Belanger, asked about the trial and adoption process for DefenCath, seeking to understand the differences between inpatient and outpatient segments. He also inquired if the TDAPA reimbursement process is operating seamlessly and if most operators are familiar with it.

    Answer

    CEO Joseph Todisco explained that while TDAPA systems are in place, some smaller operators still require education on the process. EVP & Chief Clinical Strategy and Operations Officer Elizabeth Masson-Hurlburt detailed the adoption differences, noting the inpatient process is longer due to P&T committees and EMR integration, whereas outpatient adoption can be faster but still requires significant operational rollout, training, and protocol development.

    Ask Fintool Equity Research AI